Abstracts tagged "Crystal-induced arthritis"

Abstract Number: 0278 • ACR Convergence 2024
Efficacy and Safety of Genakumab versus Compound Betamethasone in Gout: The GUARD-1 Study
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Songping Li⁸, Songbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, Zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang, China, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro China Central Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shenyang, China (People's Republic), ⁶Department of Rheumatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China, Haikou, China (People's Republic), ⁷Department of Rheumatology, The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of Ganna Medical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department of Rheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: The GUARD (Genakumab in high Uric Acid-induced Arthritis/goutfor Resolution and Delay study) program was designed to investigate the efficacy and safety of Genakumab, a…
Abstract Number: 2562 • ACR Convergence 2024
Efficacy and Safety of Tocilizumab in the Treatment of Chronic Inflammatory Forms of CPPD: Retrospective Study of 55 Cases
Sophie Carrabin¹, Margaux Houze², Charlotte Jauffret³, Thomas Bardin⁴, Hang Korng Ea⁴, Frédéric Lioté⁴, Pascal Richette⁵, Tristan Pascart² and Augustin Latourte⁶, ¹Hôpital Lariboisière APHP.Nord, Paris, Paris, France, ²Lille Catholic University, Lille, France, ³Lille Catholic University, Lille, Nord-Pas-de-Calais, France, ⁴Hôpital Lariboisière APHP.Nord, Paris, France, ⁵Lariboisière Hospital, Paris, France, ⁶AP-HP, Paris, France
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a heterogeneous disease that can manifest as acute or chronic arthritis. Treatment options for chronic forms of the…
Abstract Number: 0279 • ACR Convergence 2024
Macrophage Intracellular Fates of Monosodium Urate and Calcium Pyrophosphate Crystals: Phagocytosis, Exchanged/expulsion and Dissolution of Crystals
Charles Leroy¹, Nghia Pham², François Brial³, Brenda Kischkel⁴, gwénaêlle Jayat⁵, Elena Ishow⁶, Christèle Combes⁷, Leo Joosten⁴, Augustin Latourte⁸, Pascal Richette⁹ and Hang-Korng Ea¹⁰, ¹Inserm 1132 / Université Paris Cité, levallois-perret, France, ²INSERM 1132, BIOSCAR, Lariboisière hospital, Paris, France, ³Inserm 1132/ Université Paris Cité, Paris, France, ⁴Radboudumc, Nijmegen, Netherlands, ⁵Université Paris cité / Inserm 1132, paris, France, ⁶Université de Nantes / Ceisam, Nantes, France, ⁷INP-ENSIACET, Toulouse, France, ⁸AP-HP, Paris, France, ⁹Lariboisière Hospital, Paris, France, ¹⁰Université Paris Cité, INSERM UMR 1132 BIOSCAR, Paris, France
Background/Purpose: Gout, due to the presence of monosodium urate crystals (MSU) and calcium pyrophosphate (CPP) crystal deposition disease are both responsible for recurrent inflammation flares.…
Abstract Number: 0280 • ACR Convergence 2024
Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform
Mark Russell¹, Jon Massey², Edward Roddy³, Brian MacKenna⁴, Seb Bacon⁴, Ben Goldacre⁴, Colm Andrews⁴, George Hickman⁴, Amir Mehrkar², Arti Mahto⁵, Andrew Rutherford⁶, Samir Patel¹, Maryam Adas⁷, Edward Alveyn⁷, deepak Nagra¹, Katie Bechman⁷, Joanna Ledingham⁸, Joanna Hudson⁹, Sam Norton¹, Andrew Cope⁷ and James Galloway¹⁰, ¹King's College London, London, England, United Kingdom, ²University of Oxford, Oxford, England, United Kingdom, ³Keele University, Keele, England, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵King's College Hospital NHS Foundation Trust, London, United Kingdom, ⁶King's College Hospital NHS Foundation Trust, London, England, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁹King's College London, King's College London, United Kingdom, ¹⁰Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Data from before the COVID-19 pandemic had shown persistently poor care for people with gout in many countries worldwide. Whether this was further exacerbated…
Abstract Number: 0281 • ACR Convergence 2024
Intra-articular Treatment Combining Sustained Release Colchicine Encapsulated in Microspheres, and Ropivacaine, Is Effective in Inflammatory Arthritis in Rats
Julien GRASSOT¹, Farah MARZOUKI², Roxane HERVE³, Magali BECKLER⁴, Luca SEMERANO⁵, Natacha BESSIS⁶, Elodie RIVIERE⁷, Charles SANSON², Gauthier POULIQUEN², Philippe POULETTY⁸ and Marie-Christophe BOISSIER⁹, ¹PK MED, LYON, Rhone-Alpes, France, ²PK MED, LYON, France, ³INSERM U1125, Bobigny, France, ⁴INSERM 1125, Bobigny, France, ⁵Avicenne Teaching Hospital APHP, Bobigny, France, ⁶INSERM, Université Sorbonne Paris Nord, PARIS, France, ⁷INSERM, Université Sorbonne Paris Nord, APHP, PARIS, France, ⁸PK MED, PARIS, France, ⁹University Sorbonne Paris Nord, Bobigny, France
Background/Purpose: Gout is a common disease with a prevalence and incidence on the rise worldwide. However, approved treatments to treat acute gout flares have slow…
Abstract Number: 0282 • ACR Convergence 2024
Electronic Health Record-Based Calcium Pyrophosphate Deposition Disease Registry: A Feasibility Study
Nils Bürgisser¹, Denis Mongin², Samia Mehouachi², Delphine Sophie Courvoisier³ and Kim Lauper⁴, ¹Division of Rheumatology and internal medicine, Geneva University Hospital, Switzerland, Geneva, Switzerland, ²Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland, ³Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ⁴Geneva University Hospitals, Geneva, Switzerland
Background/Purpose: Despite its prevalence, calcium pyrophosphate deposition disease (CPPD) remains insufficiently studied. Leveraging electronic health record (EHR) data, a rich source of patient information, could…
Abstract Number: 0284 • ACR Convergence 2024
Identification of Calcium Pyrophosphate Deposition Using Ultrasonography in Patients with a Suspected Diagnosis of Seronegative Rheumatoid Arthritis
Joanna Potera¹, Angelo Gaffo², Alvin Day³, Mariana Urquiaga² and Amanda Alexander⁴, ¹University of Alabama at Birmingham, Irondale, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Dept. of Veterans Affairs, Lexington, SC, ⁴University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Calcium pyrophosphate deposition disease is a common condition that can cause chronic polyarticular inflammatory joint disease, which sometimes resembles rheumatoid arthritis. Misdiagnosis is especially…
Abstract Number: 1071 • ACR Convergence 2024
Rapid Access Microscopy and Real Time Case Discussion via a Secure Messaging App Improves Diagnostic Accuracy and Management of Acute Hot Swollen Joints
Anouchka Lewis¹, John Stack², Oisin Corish², Callum Swift², Tomás Breslin², Frank Lyons², Eavan Muldoon², Cian McDermott², Sharon Cowley², Helina Alemayehu², Oliver Boughton², Khaled Taha² and Geraldine McCarthy², ¹The Mater Misericordiae University Hospital, Dublin, Ireland, ²Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Patients with acute swollen joints are often presumed to have septic arthritis, leading to treatment with intravenous antibiotics and arthroscopic washout. Previously at our…
Abstract Number: 1083 • ACR Convergence 2024
Comparison of a Handheld Ultrasound Device with Cart-Based Ultrasound for the Assessment of Gout Lesions in People with Established Gout
Rachel Murdoch¹, Lene Terslev², Julia Martin³, Borislav Mihov¹, Gregory Gamble¹, Søren Torp-Pedersen⁴, Anne Horne¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ³Te Whatu Ora Te Toka Tumai, Auckland, New Zealand, ⁴Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Ultrasound is frequently used in rheumatology practice to assist with the diagnosis of rheumatic and musculoskeletal diseases. In patients with gout, it allows visualization…
Abstract Number: 1092 • ACR Convergence 2024
Chronic Kidney Disease Is Associated with Increased Glucose Uptake-associated Metabolic Activity of Visceral Adipose and Subcutaneous Adipose Tissue in Gout Patients
Shunya Kaneshita¹, Sho Fukui², Soheil Niku³, KWANGHOON LEE⁴, Ernest Belezzuoli³, Robert Terkeltaub⁵ and Monica Guma⁶, ¹UCSD, Miyazu city, Kyoto, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³UCSD, La Jolla, ⁴UCSD, San Diego, CA, ⁵Retired, San Diego, CA, ⁶UCSD, La Jolla, CA
Background/Purpose: Gout, a condition characterized by elevated uric acid levels, is linked to multiple complications, including coronary artery disease, hypertension, and type 2 diabetes mellitus.…
Abstract Number: 1094 • ACR Convergence 2024
Longitudinal Analysis of Serum Urate in Prediabetic Phase
Javier Marrugo¹, Leah Santacroce¹, Misti Paudel², Sho Fukui³, Sara Tedeschi¹ and Daniel Solomon⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: More than 460 million people worldwide are currently living with prediabetes, a condition that not only predisposes individuals to diabetes (DM) but also to…
Abstract Number: 1095 • ACR Convergence 2024
The Incidence of Gout Among Individuals with Hyperuricemia over Time – an Insight from a Nationwide Cohort Study
Shay Brikman¹, Amir Bieber², Liel Serfaty, MA³, Ran Abuhasira, MD, PhD⁴, Nadav Rappoport⁵ and Naomi Schlesinger⁶, ¹Emek Medical Center, Afula, Israel, ²Emek Medical Center, Clalit Health Services, Raanana, Israel, ³Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, ⁴Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶University of Utah, Salt Lake City, UT
Background/Purpose: Hyperuricemia is considered the most important risk factor for developing Gout, the most common adult inflammatory arthritis. Hyperuricemia is defined by a serum urate…
Abstract Number: 1121 • ACR Convergence 2023
Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials
Roba Ghossan¹, Ouidade Aitisha Tabesh², Fouad Fayad², Pascal Richette³ and Thomas Bardin⁴, ¹COCHIN HOSPITAL, Paris, France, ²Hotel Dieu de France, Beirut, Lebanon, ³Lariboisière Hospital, Paris, France, ⁴Université de Paris Cité, Paris, France
Background/Purpose: To this date, a causal relationship between febuxostat and cardiovascular disease remains controversial as comparison between trials can be challenging and may lead to…
Abstract Number: 0048 • ACR Convergence 2023
Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Mohnish Alishala¹, Stephen Calderon¹, Anyan Chen¹, Monica Guma², Christopher glass¹ and Isidoro Cobo¹, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA
Background/Purpose: Gout is the most frequent form of inflammatory arthritis, with episodes of self-resolving acute inflammation in the joint caused by the deposition of monosodium…
Abstract Number: 0246 • ACR Convergence 2023
Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies
Herbert Baraf¹, Alan Kivitz², Sheri Rhodes³, Sheldon Leung⁴, Olu Folarin⁴, Tania Gonzalez-Rivera⁵, Joanna Sobierska⁵, Jacquie Christie⁵, Anand Patel⁶, Wesley DeHaan⁴, Rehan Azeem⁴ and Peter Traber⁷, ¹The Center for Rheumatology and Bone Research, George Washington University, Rheumatology, Bethesda, MD, ²Altoona Center for Clinical Research, Duncansville, PA, ³Selecta Biosciences, Atlanta, GA, ⁴Selecta Biosciences, Inc., Watertown, MA, ⁵Swedish Orphan Biovitrum (Sobi), Stockholm, Sweden, ⁶Pioneer Research Solutions, Houston, TX, ⁷Selecta Biosciences, Gladwyne, PA
Background/Purpose: In patients with refractory gout, the inability to maintain serum uric acid (sUA) levels < 6 mg/dL leads to severe clinical manifestations for which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].